Literature DB >> 2139667

Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice.

S L Hofmann1, D L Eaton, M S Brown, W J McConathy, J L Goldstein, R E Hammer.   

Abstract

Lp(a) lipoprotein purified from human plasma bound with high affinity to isolated bovine LDL receptors on nitrocellulose blots and in a solid-phase assay. Lp(a) also competed with 125I-LDL for binding to human LDL receptors in intact fibroblasts. Binding led to cellular uptake of Lp(a) with subsequent stimulation of cholesterol esterification. After intravenous injection, human Lp(a) was cleared slowly from the plasma of normal mice. The clearance was markedly accelerated in transgenic mice that expressed large amounts of LDL receptors. We conclude that the covalent attachment of apo(a) to apo B-100 in Lp(a) does not interfere markedly with the ability of apo B-100 to bind to the LDL receptor and that this receptor has the potential to play a major role in clearance of Lp(a) from the circulation of intact humans.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139667      PMCID: PMC296603          DOI: 10.1172/JCI114602

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Binding of LP(a) to the low density lipoprotein receptor of human fibroblasts.

Authors:  L Havekes; B J Vermeer; T Brugman; J Emeis
Journal:  FEBS Lett       Date:  1981-09-28       Impact factor: 4.124

3.  Uptake of Lp (a) lipoprotein by cultured fibroblasts.

Authors:  C H Floren; J J Albers; E L Bierman
Journal:  Biochem Biophys Res Commun       Date:  1981-09-30       Impact factor: 3.575

4.  Receptor-mediated endocytosis of low-density lipoprotein in cultured cells.

Authors:  J L Goldstein; S K Basu; M S Brown
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Purification of the LDL receptor.

Authors:  W J Schneider; J L Goldstein; M S Brown
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

6.  A monoclonal-antibody-based enzyme-linked immunosorbent assay of lipoprotein(a).

Authors:  W L Wong; D L Eaton; A Berloui; B Fendly; P E Hass
Journal:  Clin Chem       Date:  1990-02       Impact factor: 8.327

7.  Immunoblot analysis of low density lipoprotein receptors in fibroblasts from subjects with familial hypercholesterolemia.

Authors:  U Beisiegel; W J Schneider; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1982-11-10       Impact factor: 5.157

8.  Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptor.

Authors:  K Maartmann-Moe; K Berg
Journal:  Clin Genet       Date:  1981-11       Impact factor: 4.438

9.  Visualization of lipoprotein receptors by ligand blotting.

Authors:  T O Daniel; W J Schneider; J L Goldstein; M S Brown
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

10.  Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man.

Authors:  F Krempler; G M Kostner; A Roscher; F Haslauer; K Bolzano; F Sandhofer
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

View more
  29 in total

1.  HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a).

Authors:  Calvin Yeang; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-05-26       Impact factor: 5.922

2.  Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients.

Authors:  Patrick M Moriarty; Stephen A Varvel; Philip L S M Gordts; Joseph P McConnell; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-01-05       Impact factor: 8.311

3.  Enhanced macrophage uptake of lipoprotein(a) after Ca2+-induced aggregate-formation.

Authors:  S Tanaka; A Yashiro; H Tasaki; Y Nakashima
Journal:  Lipids       Date:  1998-04       Impact factor: 1.880

4.  Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB.

Authors:  Y Y van der Hoek; A Lingenhel; H G Kraft; J C Defesche; J J Kastelein; G Utermann
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

5.  A PvuII polymorphism of the low density lipoprotein receptor gene is not associated with plasma concentrations of low density lipoproteins including LP(a).

Authors:  I C Klausen; P S Hansen; L U Gerdes; N Rüdiger; N Gregersen; O Faergeman
Journal:  Hum Genet       Date:  1993-03       Impact factor: 4.132

Review 6.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

7.  The apolipoprotein B3304-3317 peptide as an inhibitor of the lipoprotein (a):apolipoprotein B-containing lipoprotein interaction.

Authors:  V N Trieu; U Olsson; W J McConathy
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

8.  Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma.

Authors:  P Henriksson; B Angelin; L Berglund
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

9.  Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a).

Authors:  H Dieplinger; C Lackner; F Kronenberg; C Sandholzer; K Lhotta; F Hoppichler; H Graf; P König
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

10.  Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events.

Authors:  Jacqueline Suk Danik; Nader Rifai; Julie E Buring; Paul M Ridker
Journal:  J Am Coll Cardiol       Date:  2008-07-08       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.